SCHEMBL21026259

SCHEMBL21026259

COCCn1cnc2ccc(C(C)(C)C)cc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
LMNA P02545 7/20 0.43
SMN1; SMN2 Q16637 6/20 0.43
RAB9A P51151 3/20 0.43
NPC1 O15118 2/20 0.43
MTNR1A P48039 1/20 0.41
MTNR1B P49286 1/20 0.41
BRD4 O60885 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
POLB P06746 1/20 0.40
GRIN2B Q13224 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
HTT P42858 3/20 0.39
MAPT P10636 2/20 0.39
TP53 P04637 1/20 0.39
GAA P10253 1/20 0.38
PKM P14618 1/20 0.38
USP2 O75604 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23479575 0.82 TDP1 (0.49) MEN1KMT2ALMNASMN1; SMN2RAB9A
SCHEMBL17678350 0.81 MEN1 (0.68) MEN1KMT2ALMNASMN1; SMN2RAB9A
SCHEMBL21025781 0.80 HTR6 (0.42) MEN1KMT2ALMNAMTNR1AMTNR1B
SCHEMBL5695836 0.79 MEN1 (0.61) MEN1KMT2ALMNASMN1; SMN2RAB9A
SCHEMBL21025786 0.78 TGFBR1 (0.43) LMNASMN1; SMN2TDP1HTTMAPT
SCHEMBL21025783 0.78 KDM4E (0.48) SMN1; SMN2TDP1PRPS1
SCHEMBL5695751 0.76 MEN1 (0.57) MEN1KMT2ALMNASMN1; SMN2RAB9A
SCHEMBL30914205 0.76 MEN1 (0.57) MEN1KMT2ALMNASMN1; SMN2RAB9A
SCHEMBL5695731 0.76 MEN1 (0.57) MEN1KMT2ALMNASMN1; SMN2RAB9A
SCHEMBL21025782 0.76 SIGMAR1 (0.48) SMN1; SMN2L3MBTL1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190151312-A1 HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. 2019-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190151312-A1 HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES HPSE, GAA, MAN2B1 MEN1 2566/4885KMT2A 4081/4885LMNA 2070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.